title: Delayed graft function is reduced with antithymocyte globulin induction in pediatric kidney transplantation.
abstract: Reduction of delayed graft function (DGF) is critical to the success of renal transplantation. We report graft outcomes with antithymocyte globulin (ATG) induction compared with using interleukin-2 receptor antagonist basiliximab (IL-2RA). Twelve pediatric patients received a pediatric deceased donor kidney. We treated them with ATG (group A, ATG; n = 6) or IL-2RA (group B, n = 6). DGF was observed in 0 cases (group A) and in 6 cases (group B), which showed a mean of 7 +/- 3 days (P < .001). In group A, lymphopenia occurred routinely resolving after 3-6 months, none with serious infection. The incidence of opportunistic infections was 0% in both groups. One-year patient and graft survivals were 100% in both groups. ATG induction significantly reduced the incidence of delayed graft function. Both induction treatments led to a good patient and graft survival.
authors.affiliation: Pediatric Nephrology Department, Hospital Vall d'Hebron, Barcelona, Spain. rvilaltacasas@hotmail.com
authors.forename: R
authors.initials: R
authors.lastname: Vilalta
authors.forename: E
authors.initials: E
authors.lastname: Lara
authors.forename: A
authors.initials: A
authors.lastname: Madrid
authors.forename: S
authors.initials: S
authors.lastname: Chocron
authors.forename: A
authors.initials: A
authors.lastname: Vazquez
authors.forename: A
authors.initials: A
authors.lastname: Casquero
authors.forename: J
authors.initials: J
authors.lastname: Nieto
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000276:immunology* / Q000627:therapeutic use*; D000077552:Basiliximab; D002102:Cadaver; D002648:Child; D002675:Child, Preschool; D051799:Delayed Graft Function / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006085:Graft Survival / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D007674:Kidney Diseases / Q000145:classification / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use; D014019:Tissue Donors
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D016559:Tacrolimus